Therapeutic Asset Ratings

329 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Cyclophosphamide Melanoma	Primmune Therapeutics, Inc.	P4	BB (70)
DACARBAZINE Melanoma	Suzhou BlueHorse Therapeutics Co., Ltd.	P3	BB (70)
Epirubicin Melanoma	Primmune Therapeutics, Inc.	P4	BB (69)
Ipilimumab Melanoma	M.D. Anderson Cancer Center	P4	BB (69)
Nivolumab Melanoma	Bristol-Myers Squibb	P4	BB (69)
Pembrolizumab Melanoma	Biocon Biologics UK PLC	P4	BB (69)
gsk1120212 Melanoma	Xynomic Pharmaceuticals, Inc.	P4	BB (68)
Tunlametinib Melanoma	Fudan University	P4	BB (67)
Dabrafenib Melanoma	Intergruppo Melanoma Italiano	P4	BB (66)
VEMURAFENIB Melanoma	Cancer Research UK	P3	BB (66)
Carboplatin Melanoma	Rapa Therapeutics LLC	P3	BB (64)
INTERFERON ALFA-2B Melanoma	Roswell Park Cancer Institute	P3	BB (64)
Toripalimab Melanoma	West China Hospital	P3	BB (64)
FLUOROURACILUM Melanoma	Neonc Technologies, Inc.	P2	BB (64)
Relatlimab Melanoma	Bristol-Myers Squibb	P4	B (63)
Irinotecan Melanoma	Pfizer	P2	B (63)
Polyiclc Melanoma	Washington University School of Medicine	P2	B (63)
(+)-VINCRISTINE Melanoma	Pfizer	P2	B (63)
CIS-DIAMMINEDICHLOROPLATINUM II Melanoma	Suzhou BlueHorse Therapeutics Co., Ltd.	P3	B (62)
Cobimetinib Melanoma	ImmVira Pharma Co. Ltd	P3	B (62)
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE Melanoma	Amgen	P3	B (62)
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER Melanoma	Fujian Cancer Hospital	P3	B (62)
LENVATINIB Melanoma	Diwakar Davar	P3	B (62)
TIL Melanoma	City of Hope Medical Center	P3	B (62)
bdb001 Melanoma	Institut Bergonié	P2	B (62)

Showing 1 to 25 of 329 assets

PreviousPage 1 of 14Next